Shanghai Henlius Biotech Inc.

Fbd Biologics Limited

Chi-Ling Tseng

Pei-Hua Lin

Weidong Jiang

Pan-Hsien Kuo

Han-Fang Teng

Jiin-Tarng Wang

Zong Sean Juo

This disclosure relates to engineered SIRPα variants, and methods of use thereof.

Engineered SIRPα variants and methods of use thereof

Provided are anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-1 antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Anti-PD-1 antibodies

Provided are anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-L1 antibodies, variants, mutants, or antigen binding fragments thereof, and related expression vectors, and host cells. Provided are methods of making anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Anti-PD-L1 antibodies and variants

Growing community of inventors

Taipei, Taiwan

Chi-Ling Tseng